• Like
3 stocks that soared stupendously this week  6-27-14
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

3 stocks that soared stupendously this week 6-27-14

  • 2,721 views
Published

3 of this week's best-performing health-care stocks

3 of this week's best-performing health-care stocks

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
2,721
On SlideShare
0
From Embeds
0
Number of Embeds
10

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

Transcript

  • 1. 3 Stocks That Soared Stupendously This Week
  • 2. Americans had reason to cheer this week as the U.S. advanced to the next round of the World Cup. Shareholders of these three health-care stocks cheered on also as their investments racked up massive gains.
  • 3. Shares of the clinical stage pharmaceutical firm surged 35% this week. Aerie Pharmaceuticals (NASDAQ:AERI) Source: Yahoo! Finance
  • 4. • Aerie reported great results from its phase 2b trial of roclatan • The drug, which targets treatment of glaucoma, met all clinical endpoints in the study • Roclatan performed very well on the study’s primary endpoint, reducing mean diurnal intraocular pressures by 34% • Aerie now plans to advance the drug to a late-stage clinical study Why Aerie shares went airborne
  • 5. Shares of the biotech skyrocketed 44% higher for the week. Vertex Pharmaceuticals (NASDAQ:VRTX) Source: Yahoo! Finance
  • 6. • Vertex announced positive results from two phase 3 studies • Both studies focused on use of a VX- 809/Kalydeco combo in treating cystic fibrosis • Patients taking the drug combo experienced statistically significant improvement in forced expiratory volume in one second, a respiratory measure known as FEV1 • Next steps for Vertex include filing for regulatory approval in both the U.S. and Europe Why Vertex shares vaulted higher
  • 7. Shares of the medical products supplier soared almost 97% higher this week. Medical Action Industries (NASDAQ:MDCI) Source: Yahoo! Finance
  • 8. • Owens & Minor (NYSE:OMI) announced plans to acquire Medical Action Industries • The large health-care logistics company will pay $13.80 per share – reflecting a $208 million valuation of Medical Action net of cash • Owens & Minor stated that the acquisition will create between $10 million and $12 million in cost synergies by the end of 2016 • Around 45% of Medical Action’s sales over the last year were to Owens & Minor Why Medical Action shares took off
  • 9. • Medical Action’s stock has likely seen about as much action as it’s going to get • Aerie shares could continue to perform well after the great results for roclatan • The nod for best pick, though, goes to Vertex • Vertex has a good shot of winning regulatory approval after the solid results from the phase 3 studies for its VX-809/Kalydeco combo • Some profit-taking is quite possible, but shares could resume their climb over the next few months in anticipation of approval decisions in the U.S. and Europe Best pick to keep soaring?
  • 10. Cable’s going away. But do you know how to profit? There’s $2.2 trillion at stake. Find out which 3 companies stand ready to benefit -- and they’re not Netflix, Google, and Apple!